Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 13, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Second Quarter 2019 Results

TORONTO and CAMBRIDGE, Mass., Aug. 13, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
July 24, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders

TORONTO and CAMBRIDGE, Mass., July 24, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
July 18, 2019 15:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Highlights Data for PMN310 at AAIC 2019

TORONTO and CAMBRIDGE, Mass., July 18, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
July 10, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Present Data at 2019 Alzheimer’s Association International Conference

TORONTO and CAMBRIDGE, Mass., July 10, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
July 09, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences’ Data for Alzheimer’s Disease Clinical Candidate PMN310 Published in Scientific Reports

TORONTO and CAMBRIDGE, Mass., July 09, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
June 27, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences’ PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies

TORONTO, Ontario and CAMBRIDGE, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
June 26, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Closing Private Placement

NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, June 26, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a...
June 19, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Appoints Renowned Parkinson’s Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board

TORONTO and CAMBRIDGE, Mass., June 19, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
June 05, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Presents Lead Program for Alzheimer’s Disease at Prestigious Keystone Symposia Scientific Conference

TORONTO and CAMBRIDGE, Mass., June 05, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
May 29, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences’ Eugene Williams to Present at JLABS’ Conference on Innovations in Neurodegenerative Diseases

TORONTO and CAMBRIDGE, Mass., May 29, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...